| Year |
Citation |
Score |
| 2023 |
Wang L, Chelakkot VS, Newhook N, Tucker S, Hirasawa K. Inflammatory cell death induced by 5-aminolevulinic acid-photodynamic therapy initiates anticancer immunity. Frontiers in Oncology. 13: 1156763. PMID 37854679 DOI: 10.3389/fonc.2023.1156763 |
0.82 |
|
| 2023 |
Duncan JKS, Xu D, Licursi M, Joyce MA, Saffran HA, Liu K, Gohda J, Tyrrell DL, Kawaguchi Y, Hirasawa K. Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection. Frontiers in Immunology. 14: 930086. PMID 37197656 DOI: 10.3389/fimmu.2023.930086 |
0.782 |
|
| 2021 |
Oraby AK, Gardner CL, Needle RF, Kofahi HM, Everard KR, Taylor NGA, Rutihinda SG, Barry JP, Hirasawa K, Georghiou PE, Russell RS. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture. Microbiology Spectrum. e0043921. PMID 34319169 DOI: 10.1128/Spectrum.00439-21 |
0.752 |
|
| 2020 |
Chelakkot VS, Liu K, Yoshioka E, Saha S, Xu D, Licursi M, Dorward A, Hirasawa K. MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1α-FECH axes. Scientific Reports. 10: 22124. PMID 33335181 DOI: 10.1038/s41598-020-79144-x |
0.8 |
|
| 2019 |
Chelakkot VS, Som J, Yoshioka E, Rice CP, Rutihinda SG, Hirasawa K. Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy. British Journal of Cancer. PMID 31551581 DOI: 10.1038/S41416-019-0586-3 |
0.719 |
|
| 2018 |
Fogarty LC, Flemmer RT, Geizer BA, Licursi M, Karunanithy A, Opferman JT, Hirasawa K, Vanderluit JL. Mcl-1 and Bcl-xL are essential for survival of the developing nervous system. Cell Death and Differentiation. PMID 30361616 DOI: 10.1038/S41418-018-0225-1 |
0.7 |
|
| 2018 |
Yoshioka E, Chelakkot VS, Licursi M, Rutihinda SG, Som J, Derwish L, King JJ, Pongnopparat T, Mearow K, Larijani M, Dorward AM, Hirasawa K. Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway. Theranostics. 8: 2134-2146. PMID 29721068 DOI: 10.7150/Thno.22641 |
0.739 |
|
| 2016 |
Licursi M, Alberto CO, Dias A, Hirasawa K, Hirasawa M. High-fat diet-induced downregulation of anorexic leukemia inhibitory factor in the brain stem. Obesity (Silver Spring, Md.). PMID 27663886 DOI: 10.1002/Oby.21647 |
0.694 |
|
| 2016 |
Komatsu Y, Derwish L, Hirasawa K. IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA. Plos One. 11: e0160529. PMID 27508303 DOI: 10.1371/Journal.Pone.0160529 |
0.82 |
|
| 2015 |
Komatsu Y, Hirasawa K, Christian SL. Global gene analysis identifying genes commonly regulated by the Ras/Raf/MEK and type I IFN pathways. Genomics Data. 4: 84-7. PMID 26484185 DOI: 10.1016/J.Gdata.2015.03.012 |
0.82 |
|
| 2015 |
Licursi M, Carmona-Martinez RA, Razavi S, Hirasawa K. Promotion of Viral IRES-Mediated Translation Initiation under Mild Hypothermia. Plos One. 10: e0126174. PMID 25951166 DOI: 10.1371/Journal.Pone.0126174 |
0.695 |
|
| 2015 |
AbuSara N, Razavi S, Derwish L, Komatsu Y, Licursi M, Hirasawa K. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells. Cancer Letters. 357: 575-81. PMID 25497010 DOI: 10.1016/J.Canlet.2014.12.017 |
0.813 |
|
| 2015 |
Komatsu Y, Christian SL, Ho N, Pongnopparat T, Licursi M, Hirasawa K. Oncogenic Ras inhibits IRF1 to promote viral oncolysis. Oncogene. 34: 3985-93. PMID 25347735 DOI: 10.1038/Onc.2014.331 |
0.853 |
|
| 2015 |
Komatsu Y, Christian SL, Ho N, Pongnopparat T, Licursi M, Hirasawa K. 628. Oncogenic Ras Inhibits IRF1 To Promote Viral Oncolysis Molecular Therapy. 23: S249. DOI: 10.1016/S1525-0016(16)34237-X |
0.853 |
|
| 2014 |
Mostafa AA, Codner D, Hirasawa K, Komatsu Y, Young MN, Steimle V, Drover S. Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells. Plos One. 9: e87377. PMID 24475282 DOI: 10.1371/Journal.Pone.0087377 |
0.764 |
|
| 2012 |
Christian SL, Zu D, Licursi M, Komatsu Y, Pongnopparat T, Codner DA, Hirasawa K. Suppression of IFN-induced transcription underlies IFN defects generated by activated Ras/MEK in human cancer cells. Plos One. 7: e44267. PMID 22970192 DOI: 10.1371/Journal.Pone.0044267 |
0.839 |
|
| 2012 |
Licursi M, Komatsu Y, Pongnopparat T, Hirasawa K. Promotion of viral internal ribosomal entry site-mediated translation under amino acid starvation. The Journal of General Virology. 93: 951-62. PMID 22302880 DOI: 10.1099/Vir.0.040386-0 |
0.786 |
|
| 2011 |
Licursi M, Christian SL, Pongnopparat T, Hirasawa K. In vitro and in vivo comparison of viral and cellular internal ribosome entry sites for bicistronic vector expression. Gene Therapy. 18: 631-6. PMID 21368899 DOI: 10.1038/Gt.2011.11 |
0.787 |
|
| 2011 |
Mostafa A, Codner D, Lewis C, Hirasawa K, Christian S, Steimle V, Drover S. Abstract 804: Class II transactivator (CIITA) transcription is reduced by the ER-E2signaling pathway in breast cancer cells Cancer Research. 71: 804-804. DOI: 10.1158/1538-7445.Am2011-804 |
0.705 |
|
| 2010 |
Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, Johnston RN, Forsyth PA, Magliocco AM, Lee P, Nishikawa S, Donnelly B, Coffey M, Trpkov K, Fonseca K, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Research. 70: 2435-44. PMID 20215509 DOI: 10.1158/0008-5472.Can-09-2408 |
0.447 |
|
| 2009 |
Christian SL, Collier TW, Zu D, Licursi M, Hough CM, Hirasawa K. Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels. Journal of Virology. 83: 6717-26. PMID 19386709 DOI: 10.1128/Jvi.02213-08 |
0.821 |
|
| 2006 |
Battcock SM, Collier TW, Zu D, Hirasawa K. Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. Journal of Virology. 80: 4422-30. PMID 16611902 DOI: 10.1128/Jvi.80.9.4422-4430.2006 |
0.739 |
|
| 2006 |
Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, Lake BB, Kao KR. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2216-23. PMID 16609037 DOI: 10.1158/1078-0432.CCR-05-2433 |
0.308 |
|
| 2004 |
Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proceedings of the National Academy of Sciences of the United States of America. 101: 11099-104. PMID 15263068 DOI: 10.1073/Pnas.0404310101 |
0.565 |
|
| 2004 |
Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic. Cancer Biology & Therapy. 3: 734-8. PMID 15197356 DOI: 10.4161/Cbt.3.8.963 |
0.424 |
|
| 2003 |
Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Research. 63: 348-53. PMID 12543787 |
0.377 |
|
| 2002 |
Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PW, Kossakowska AE. Reovirus therapy of lymphoid malignancies. Blood. 100: 4146-53. PMID 12393565 DOI: 10.1182/Blood-2002-02-0503 |
0.461 |
|
| 2002 |
Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW. Reovirus oncolysis of human breast cancer. Human Gene Therapy. 13: 641-52. PMID 11916487 DOI: 10.1089/10430340252837233 |
0.476 |
|
| 2002 |
Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Research. 62: 1696-701. PMID 11912142 |
0.429 |
|
| Show low-probability matches. |